Last reviewed · How we verify
Combivir+Reyataz
Combivir+Reyataz is a Antiretroviral combination therapy (NRTI + protease inhibitor) Small molecule drug developed by Hospital Clinic of Barcelona. It is currently FDA-approved for HIV-1 infection in treatment-naïve or treatment-experienced patients.
This combination of two antiretroviral drugs inhibits HIV reverse transcriptase and protease to suppress viral replication.
This combination of two antiretroviral drugs inhibits HIV reverse transcriptase and protease to suppress viral replication. Used for HIV-1 infection in treatment-naïve or treatment-experienced patients.
At a glance
| Generic name | Combivir+Reyataz |
|---|---|
| Sponsor | Hospital Clinic of Barcelona |
| Drug class | Antiretroviral combination therapy (NRTI + protease inhibitor) |
| Target | HIV reverse transcriptase; HIV protease |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Combivir (lamivudine/zidovudine) contains two nucleoside reverse transcriptase inhibitors (NRTIs) that block HIV reverse transcriptase, while Reyataz (atazanavir) is a protease inhibitor that prevents HIV protease from cleaving viral polyproteins. Together, they reduce HIV viral load by targeting two critical steps in the HIV replication cycle.
Approved indications
- HIV-1 infection in treatment-naïve or treatment-experienced patients
Common side effects
- Nausea
- Diarrhea
- Headache
- Hyperbilirubinemia
- Lipodystrophy
- Peripheral neuropathy
Key clinical trials
- Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone (PHASE3)
- IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum Women (PHASE4)
- Preventing Sexual Transmission of HIV With Anti-HIV Drugs (PHASE3)
- Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings (PHASE4)
- A Study Comparing The Safety, Tolerability and Efficacy of Trizivir VS Combivir & Atazanavir In Subjects With HIV (PHASE4)
- Low Dose Atazanavir/r Versus Standard Dose Atazanavir/r (LASA) (PHASE4)
- Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir (PHASE3)
- Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Combivir+Reyataz CI brief — competitive landscape report
- Combivir+Reyataz updates RSS · CI watch RSS
- Hospital Clinic of Barcelona portfolio CI
Frequently asked questions about Combivir+Reyataz
What is Combivir+Reyataz?
How does Combivir+Reyataz work?
What is Combivir+Reyataz used for?
Who makes Combivir+Reyataz?
What drug class is Combivir+Reyataz in?
What development phase is Combivir+Reyataz in?
What are the side effects of Combivir+Reyataz?
What does Combivir+Reyataz target?
Related
- Drug class: All Antiretroviral combination therapy (NRTI + protease inhibitor) drugs
- Target: All drugs targeting HIV reverse transcriptase; HIV protease
- Manufacturer: Hospital Clinic of Barcelona — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Virology
- Indication: Drugs for HIV-1 infection in treatment-naïve or treatment-experienced patients
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing